Overview

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
NGP 555 is a small molecule preventative therapy aimed at reducing Alzheimer's disease amyloid buildup by targeting Abeta 42 production.
Phase:
Phase 1
Details
Lead Sponsor:
NeuroGenetic Pharmaceuticals Inc